INVIVYD INC. - COMMON

Invivyd Announces Changes to Executive Team

03 2 2023 06:30:00 提供 Nasdaq GlobeNewswire

Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop

19 12 2022 06:00:00 提供 Nasdaq GlobeNewswire

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

06 12 2022 15:01:00 提供 Nasdaq GlobeNewswire

Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19

17 11 2022 06:00:01 提供 Nasdaq GlobeNewswire

Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights

10 11 2022 15:01:00 提供 Nasdaq GlobeNewswire

Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference

09 11 2022 06:00:03 提供 Nasdaq GlobeNewswire

Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights

02 11 2022 06:00:02 提供 Nasdaq GlobeNewswire

Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors

24 10 2022 15:01:00 提供 Nasdaq GlobeNewswire

Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform

13 10 2022 15:01:00 提供 Nasdaq GlobeNewswire

Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022

12 10 2022 15:01:00 提供 Nasdaq GlobeNewswire

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants

12 9 2022 06:15:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Announces Corporate Name Change to Invivyd

12 9 2022 06:00:01 提供 Nasdaq GlobeNewswire

Adagio Therapeutics to Participate in Upcoming Investor Conferences

06 9 2022 15:01:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

15 8 2022 05:30:00 提供 Nasdaq GlobeNewswire

Adagio Announces David Hering Named Permanent Chief Executive Officer and Director

05 7 2022 06:25:58 提供 Nasdaq GlobeNewswire

Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors

01 7 2022 05:30:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Reports First Quarter 2022 Financial Results

13 5 2022 05:30:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request

14 4 2022 06:45:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization

30 3 2022 05:30:00 提供 Nasdaq GlobeNewswire

Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders

18 3 2022 17:33:15 提供 Nasdaq GlobeNewswire